Once again, you can't compare to those pharma who has phase 1 & 2 trials lined up.... Innv is more of a retail. We all know there is no jackpot. Fluticare can bring some.. but $15m a year is still a peanut for investors.. i agree the current price has been unfair.. but no news no buy......even with the fluticare approval, this will only go .30?? max for now... there is a saying sell the news!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.